Search
Research
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeRespiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active.
Research
The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: A case - Control studyRespiratory viruses, particularly respiratory syncytial virus and human metapneumovirus, are major contributors to pneumonia in Australian children
Research
AMEND study protocol: A case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adultsThis study aims to address this evidence gap by assessing the clinical, physical, neurocognitive, economic and societal impact of invasive meningococcal disease
Research
Postvaccination Febrile Seizure Severity and OutcomeVaccine-proximate febrile seizures accounted for a small proportion of all febrile seizures hospital presentations
Research
Influenza-Associated Encephalitis/Encephalopathy Identified by the Australian Childhood Encephalitis Study 2013-2015We aimed to describe case of Influenza associated encephalitis/encephalopathy identified by the Australian Childhood Encephalitis study
Research
Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccinationWe studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in children, 3-5 years of age, in community controls of a similar age.
Research
No evidence for impaired humoral immunity to pneumococcal proteins in Australian Aboriginal children with otitis mediaConserved vaccine candidate proteins from S.pneumoniae induce serum and salivary antibody responses in Aboriginal and non-Aboriginal children with history of OM
Research
Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 studyImmune responses after the initial vaccination persisted for the 12 months studied, with little additional response after the booster dose at 6 months
Research
Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in AustraliaOur population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection
Research
Otitis-prone children produce functional antibodies to pneumolysin and pneumococcal polysaccharidesThe production of functional antipneumococcal antibodies in otitisprone children demonstrates that they respond to the current pneumococcal conjugate vaccine (PCV)and are likely to respond to pneumolysin-based vaccines as effectively as healthy children.